These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37902122)
81. Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease. Karalis DG Curr Opin Lipidol; 2023 Dec; 34(6):252-258. PubMed ID: 37594008 [TBL] [Abstract][Full Text] [Related]
82. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM Med Hypotheses; 2018 Dec; 121():60-63. PubMed ID: 30396495 [TBL] [Abstract][Full Text] [Related]
83. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053 [TBL] [Abstract][Full Text] [Related]
84. Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile: Findings From a Familial Hypercholesterolemia Pig Model. Hoogendoorn A; den Hoedt S; Hartman EMJ; Krabbendam-Peters I; Te Lintel Hekkert M; van der Zee L; van Gaalen K; Witberg KT; Dorst K; Ligthart JMR; Drouet L; Van der Heiden K; van Lennep JR; van der Steen AFW; Duncker DJ; Mulder MT; Wentzel JJ Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2338-2352. PubMed ID: 31554418 [TBL] [Abstract][Full Text] [Related]
85. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. Harada-Shiba M; Ohtake A; Sugiyama D; Tada H; Dobashi K; Matsuki K; Minamino T; Yamashita S; Yamamoto Y J Atheroscler Thromb; 2023 May; 30(5):531-557. PubMed ID: 36682777 [TBL] [Abstract][Full Text] [Related]
86. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Vallejo-Vaz AJ; Packard CJ; Ference BA; Santos RD; Kastelein JJP; Stein EA; Catapano AL; Pedersen TR; Watts GF; Ray KK Atherosclerosis; 2021 Mar; 320():1-9. PubMed ID: 33497862 [TBL] [Abstract][Full Text] [Related]
87. LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy. Hamasaki M; Sakane N; Hara K; Kotani K J Clin Lab Anal; 2021 Nov; 35(11):e24056. PubMed ID: 34652028 [TBL] [Abstract][Full Text] [Related]
91. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population. Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165 [TBL] [Abstract][Full Text] [Related]
92. Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a). Safarova MS; Moriarty PM Curr Atheroscler Rep; 2023 Jul; 25(7):391-404. PubMed ID: 37273067 [TBL] [Abstract][Full Text] [Related]
93. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. Benn M; Watts GF; Tybjaerg-Hansen A; Nordestgaard BG J Clin Endocrinol Metab; 2012 Nov; 97(11):3956-64. PubMed ID: 22893714 [TBL] [Abstract][Full Text] [Related]
94. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P; Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203 [TBL] [Abstract][Full Text] [Related]
95. Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania. Vlad CE; Foia L; Florea L; Costache II; Covic A; Popescu R; Reurean-Pintilei D; Covic A Lipids Health Dis; 2021 Jan; 20(1):4. PubMed ID: 33430859 [TBL] [Abstract][Full Text] [Related]
96. Electronic health records to facilitate continuous detection of familial hypercholesterolemia. Pepplinkhuizen S; Ibrahim S; Vink R; Groot B; Stroes ESG; Bax WA; Cornel JH Atherosclerosis; 2020 Oct; 310():83-87. PubMed ID: 32927124 [TBL] [Abstract][Full Text] [Related]
97. Atherosclerotic cardiovascular disease burden in patients with familial hypercholesterolemia: interpretation of data on involvement of different vascular beds. Dobrowolski P; Kabat M; Kępka C; Januszewicz A; Prejbisz A Pol Arch Intern Med; 2022 Apr; 132(4):. PubMed ID: 35485652 [TBL] [Abstract][Full Text] [Related]
98. Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Tada H; Kaneko H; Suzuki Y; Okada A; Takeda N; Fujiu K; Morita H; Ako J; Node K; Takeji Y; Takamura M; Yasunaga H; Komuro I Eur J Clin Invest; 2024 Feb; 54(2):e14119. PubMed ID: 37916502 [TBL] [Abstract][Full Text] [Related]
99. Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Tada H; Okada H; Nohara A; Yamagishi M; Takamura M; Kawashiri MA Circ J; 2021 Oct; 85(11):2073-2078. PubMed ID: 34011825 [TBL] [Abstract][Full Text] [Related]